BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 25537508)

  • 21. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth.
    Takayama K; Tsutsumi S; Suzuki T; Horie-Inoue K; Ikeda K; Kaneshiro K; Fujimura T; Kumagai J; Urano T; Sakaki Y; Shirahige K; Sasano H; Takahashi S; Kitamura T; Ouchi Y; Aburatani H; Inoue S
    Cancer Res; 2009 Jan; 69(1):137-42. PubMed ID: 19117996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor.
    Wu L; Runkle C; Jin HJ; Yu J; Li J; Yang X; Kuzel T; Lee C; Yu J
    Oncogene; 2014 Jan; 33(4):504-13. PubMed ID: 23318417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.
    Beke L; Nuytten M; Van Eynde A; Beullens M; Bollen M
    Oncogene; 2007 Jul; 26(31):4590-5. PubMed ID: 17237810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth.
    Shiota M; Takeuchi A; Yokomizo A; Kashiwagi E; Tatsugami K; Naito S
    J Urol; 2012 Jul; 188(1):300-6. PubMed ID: 22608750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
    Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
    Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
    Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
    Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
    Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
    Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.
    Wang D; Ding L; Wang L; Zhao Y; Sun Z; Karnes RJ; Zhang J; Huang H
    Oncotarget; 2015 Dec; 6(38):41045-55. PubMed ID: 26516927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of novel androgen receptor target genes in prostate cancer.
    Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
    Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
    Axlund SD; Lambert JR; Nordeen SK
    Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A; Fraizer GC; Piantanelli L; Saunders GF
    Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
    Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
    Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histone trimethylation of the p53 gene by expression of a constitutively active prolactin receptor in prostate cancer cells.
    Tan D; Tan S; Zhang J; Tang P; Huang J; Zhou W; Wu S
    Chin J Physiol; 2013 Oct; 56(5):282-90. PubMed ID: 24032713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.
    Babbio F; Pistore C; Curti L; Castiglioni I; Kunderfranco P; Brino L; Oudet P; Seiler R; Thalman GN; Roggero E; Sarti M; Pinton S; Mello-Grand M; Chiorino G; Catapano CV; Carbone GM; Bonapace IM
    Oncogene; 2012 Nov; 31(46):4878-87. PubMed ID: 22330138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability.
    Majumder S; Liu Y; Ford OH; Mohler JL; Whang YE
    Prostate; 2006 Sep; 66(12):1292-301. PubMed ID: 16705743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
    Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor.
    Kang Z; Jänne OA; Palvimo JJ
    Mol Endocrinol; 2004 Nov; 18(11):2633-48. PubMed ID: 15308689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src.
    Shi XB; Ma AH; Xue L; Li M; Nguyen HG; Yang JC; Tepper CG; Gandour-Edwards R; Evans CP; Kung HJ; deVere White RW
    Cancer Res; 2015 Dec; 75(24):5309-17. PubMed ID: 26573802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation.
    Wang J; Park KS; Yu X; Gong W; Earp HS; Wang GG; Jin J; Cai L
    Nucleic Acids Res; 2022 Oct; 50(19):10929-10946. PubMed ID: 36300627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.